Key facts
- FoRx Therapeutics’s last known valuation is $33.5M (Apr 2020).
- It has raised $70.7M; the latest was Later Stage VC ($50.0M) in Dec 2025.
- Notable investors include M Ventures, EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, Omega Funds — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for FoRx Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for FoRx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FoRx Therapeutics
Developer of cancer drugs designed to focus on novel DNA replication stress pathways activated in cancer. The company focuses on drugging key molecular targets involved in DNA replication stress, as a new approach toward the development of targeted anticancer drugs for cancer treatment, providing the healthcare industry with first-in-class compounds for cancer treatment.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2019
- Employees
- 36
- Website
- forxtherapeutics.com/
- Ownership
- Privately Held (backing)
FoRx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FoRx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FoRx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.